{"id":59891,"date":"2026-03-18T16:40:51","date_gmt":"2026-03-18T08:40:51","guid":{"rendered":"https:\/\/flcube.com\/?p=59891"},"modified":"2026-03-18T16:40:52","modified_gmt":"2026-03-18T08:40:52","slug":"jiuyuan-gene-engineering-secures-nmpa-approval-for-jy47-sirp%ce%b1-antibody-enters-mash-clinical-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59891","title":{"rendered":"Jiuyuan Gene Engineering Secures NMPA Approval for JY47 \u2013 SIRP\u03b1 Antibody Enters MASH Clinical Development"},"content":{"rendered":"\n<p><strong>Hangzhou Jiuyuan Gene Engineering Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2566:HKG\">HKG: 2566<\/a>) announced receiving <strong>tacit clinical approval<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for <strong>JY47<\/strong>, a <strong>SIRP\u03b1\u2011targeted monoclonal antibody<\/strong>, enabling initiation of clinical trials in <strong>metabolic dysfunction\u2011associated steatohepatitis (MASH) with liver fibrosis<\/strong> \u2013 a novel immunometabolic approach to the growing non\u2011alcoholic steatohepatitis therapeutic market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Tacit clinical approval (IND clearance)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>JY47 \u2013 SIRP\u03b1\u2011targeted monoclonal antibody<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Hangzhou Jiuyuan Gene Engineering Co., Ltd. (HKG: 2566)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Metabolic dysfunction\u2011associated steatohepatitis (MASH) with liver fibrosis<\/td><\/tr><tr><td><strong>Novelty<\/strong><\/td><td>First SIRP\u03b1\u2011targeted therapy entering MASH clinical development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>JY47<\/strong> \u2013 <strong>SIRP\u03b1 (signal regulatory protein alpha)\u2011targeted monoclonal antibody<\/strong><\/li>\n\n\n\n<li><strong>Target Biology:<\/strong><\/li>\n\n\n\n<li><strong>SIRP\u03b1<\/strong> \u2013 inhibitory receptor binding with high affinity to ligand <strong>CD47<\/strong><\/li>\n\n\n\n<li><strong>CD47\u2011SIRP\u03b1 signaling<\/strong> \u2013 critical pathway in immune regulation related to metabolic diseases<\/li>\n\n\n\n<li><strong>Therapeutic Hypothesis:<\/strong><\/li>\n\n\n\n<li><strong>SIRP\u03b1 antagonism<\/strong> modulates immune cell function<\/li>\n\n\n\n<li>Improves <strong>tissue microenvironment<\/strong> and <strong>metabolic homeostasis<\/strong><\/li>\n\n\n\n<li>Addresses MASH pathophysiology through immunometabolic mechanism vs. traditional metabolic or antifibrotic approaches<\/li>\n\n\n\n<li><strong>Preclinical Validation:<\/strong><\/li>\n\n\n\n<li>Promising therapeutic potential demonstrated in <strong>in vitro organoid models<\/strong><\/li>\n\n\n\n<li>Efficacy confirmed in <strong>in vivo MASH disease models<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-scientific-context-amp-strategic-positioning\">Scientific Context &amp; Strategic Positioning<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>Current MASH Landscape<\/th><th>JY47 Position<\/th><\/tr><\/thead><tbody><tr><td><strong>Approved Therapies<\/strong><\/td><td>Resmetirom (THR\u2011\u03b2 agonist) \u2013 first FDA\u2011approved March 2024; limited efficacy in fibrosis<\/td><td>Novel immunometabolic mechanism distinct from metabolic (THR\u2011\u03b2, FGF21) and antifibrotic approaches<\/td><\/tr><tr><td><strong>Pipeline Mechanisms<\/strong><\/td><td>GLP\u20111 RA (semaglutide), PPAR agonists, ASK1 inhibitors, CCR2\/5 antagonists<\/td><td>First\u2011in\u2011class SIRP\u03b1 targeting \u2013 immune\u2011modulatory approach to metabolic disease<\/td><\/tr><tr><td><strong>Fibrosis Focus<\/strong><\/td><td>Critical unmet need \u2013 no approved therapies halt\/reverse MASH fibrosis<\/td><td>Targets MASH <strong>with liver fibrosis<\/strong> \u2013 high\u2011risk population with limited options<\/td><\/tr><tr><td><strong>CD47\/SIRP\u03b1 Precedent<\/strong><\/td><td>Magrolimab (CD47 mAb) failed in oncology; SIRP\u03b1 targeting unexplored in metabolic disease<\/td><td>Differentiated target (SIRP\u03b1 vs. CD47) may avoid hematologic toxicity while preserving immunomodulatory benefit<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MASH Market Dynamics:<\/strong> Global MASH prevalence estimated at <strong>300+ million patients<\/strong>; addressable pharmaceutical market projected to exceed <strong>US$30 billion<\/strong> by 2030 driven by obesity epidemic and diabetes comorbidity; fibrotic MASH (F2\u2011F4) represents highest\u2011risk, highest\u2011value segment with limited therapeutic options.<\/li>\n\n\n\n<li><strong>Immunometabolic Frontier:<\/strong> JY47 enters clinic as <strong>first SIRP\u03b1\u2011targeted therapy<\/strong> in metabolic disease, validating emerging science linking innate immune dysfunction to metabolic disease progression; success would open new drug class for MASH, NASH, and potentially type 2 diabetes with inflammatory components.<\/li>\n\n\n\n<li><strong>Jiuyuan Pipeline Diversification:<\/strong> JY47 represents expansion beyond company&#8217;s established biologics portfolio (recombinant proteins, cytokines) into monoclonal antibody therapeutics and metabolic disease indications; NMPA approval demonstrates regulatory affairs capabilities for novel mechanism submissions.<\/li>\n\n\n\n<li><strong>Clinical Development Trajectory:<\/strong> Phase I safety\/tolerability expected H2 2026\u2011H1 2027; MASH clinical trials require <strong>12\u201124 month treatment duration<\/strong> for histologic endpoints (NASH resolution, fibrosis improvement); Phase IIa proof\u2011of\u2011concept data anticipated 2028\u20112029 contingent on biomarker strategy and biopsy endpoints.<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> SIRP\u03b1 mechanism provides differentiation vs. crowded GLP\u20111 and THR\u2011\u03b2 space; partnership potential with metabolic disease\u2011focused biotech or large pharma upon Phase I safety demonstration and mechanism validation in human MASH patients.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, therapeutic potential, and market expectations for JY47. Actual results may differ due to risks including safety findings in first\u2011in\u2011class mechanism, MASH trial design complexity, and competitive dynamics in the evolving NASH\/MASH therapeutic landscape.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026031700839_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026031700839_c.\"><\/object><a id=\"wp-block-file--media-aa918fa8-1a2e-417c-a0fa-c810a0c00daa\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026031700839_c.pdf\">2026031700839_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026031700839_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-aa918fa8-1a2e-417c-a0fa-c810a0c00daa\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hangzhou Jiuyuan Gene Engineering Co., Ltd. (HKG: 2566) announced receiving tacit clinical approval from China&#8217;s&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,4112,2157,76],"class_list":["post-59891","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hkg-2566","tag-jiuyuan-gene-engineering","tag-nash"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jiuyuan Gene Engineering Secures NMPA Approval for JY47 \u2013 SIRP\u03b1 Antibody Enters MASH Clinical Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hangzhou Jiuyuan Gene Engineering Co., Ltd. (HKG: 2566) announced receiving tacit clinical approval from China&#039;s National Medical Products Administration (NMPA) for JY47, a SIRP\u03b1\u2011targeted monoclonal antibody, enabling initiation of clinical trials in metabolic dysfunction\u2011associated steatohepatitis (MASH) with liver fibrosis \u2013 a novel immunometabolic approach to the growing non\u2011alcoholic steatohepatitis therapeutic market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59891\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jiuyuan Gene Engineering Secures NMPA Approval for JY47 \u2013 SIRP\u03b1 Antibody Enters MASH Clinical Development\" \/>\n<meta property=\"og:description\" content=\"Hangzhou Jiuyuan Gene Engineering Co., Ltd. (HKG: 2566) announced receiving tacit clinical approval from China&#039;s National Medical Products Administration (NMPA) for JY47, a SIRP\u03b1\u2011targeted monoclonal antibody, enabling initiation of clinical trials in metabolic dysfunction\u2011associated steatohepatitis (MASH) with liver fibrosis \u2013 a novel immunometabolic approach to the growing non\u2011alcoholic steatohepatitis therapeutic market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59891\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-18T08:40:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-18T08:40:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59891#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59891\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jiuyuan Gene Engineering Secures NMPA Approval for JY47 \u2013 SIRP\u03b1 Antibody Enters MASH Clinical Development\",\"datePublished\":\"2026-03-18T08:40:51+00:00\",\"dateModified\":\"2026-03-18T08:40:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59891\"},\"wordCount\":550,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"HKG: 2566\",\"Jiuyuan Gene Engineering\",\"NASH\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59891#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59891\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59891\",\"name\":\"Jiuyuan Gene Engineering Secures NMPA Approval for JY47 \u2013 SIRP\u03b1 Antibody Enters MASH Clinical Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-18T08:40:51+00:00\",\"dateModified\":\"2026-03-18T08:40:52+00:00\",\"description\":\"Hangzhou Jiuyuan Gene Engineering Co., Ltd. (HKG: 2566) announced receiving tacit clinical approval from China's National Medical Products Administration (NMPA) for JY47, a SIRP\u03b1\u2011targeted monoclonal antibody, enabling initiation of clinical trials in metabolic dysfunction\u2011associated steatohepatitis (MASH) with liver fibrosis \u2013 a novel immunometabolic approach to the growing non\u2011alcoholic steatohepatitis therapeutic market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59891#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59891\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59891#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jiuyuan Gene Engineering Secures NMPA Approval for JY47 \u2013 SIRP\u03b1 Antibody Enters MASH Clinical Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jiuyuan Gene Engineering Secures NMPA Approval for JY47 \u2013 SIRP\u03b1 Antibody Enters MASH Clinical Development - Insight, China&#039;s Pharmaceutical Industry","description":"Hangzhou Jiuyuan Gene Engineering Co., Ltd. (HKG: 2566) announced receiving tacit clinical approval from China's National Medical Products Administration (NMPA) for JY47, a SIRP\u03b1\u2011targeted monoclonal antibody, enabling initiation of clinical trials in metabolic dysfunction\u2011associated steatohepatitis (MASH) with liver fibrosis \u2013 a novel immunometabolic approach to the growing non\u2011alcoholic steatohepatitis therapeutic market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59891","og_locale":"en_US","og_type":"article","og_title":"Jiuyuan Gene Engineering Secures NMPA Approval for JY47 \u2013 SIRP\u03b1 Antibody Enters MASH Clinical Development","og_description":"Hangzhou Jiuyuan Gene Engineering Co., Ltd. (HKG: 2566) announced receiving tacit clinical approval from China's National Medical Products Administration (NMPA) for JY47, a SIRP\u03b1\u2011targeted monoclonal antibody, enabling initiation of clinical trials in metabolic dysfunction\u2011associated steatohepatitis (MASH) with liver fibrosis \u2013 a novel immunometabolic approach to the growing non\u2011alcoholic steatohepatitis therapeutic market.","og_url":"https:\/\/flcube.com\/?p=59891","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-18T08:40:51+00:00","article_modified_time":"2026-03-18T08:40:52+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59891#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59891"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jiuyuan Gene Engineering Secures NMPA Approval for JY47 \u2013 SIRP\u03b1 Antibody Enters MASH Clinical Development","datePublished":"2026-03-18T08:40:51+00:00","dateModified":"2026-03-18T08:40:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59891"},"wordCount":550,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","HKG: 2566","Jiuyuan Gene Engineering","NASH"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59891#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59891","url":"https:\/\/flcube.com\/?p=59891","name":"Jiuyuan Gene Engineering Secures NMPA Approval for JY47 \u2013 SIRP\u03b1 Antibody Enters MASH Clinical Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-18T08:40:51+00:00","dateModified":"2026-03-18T08:40:52+00:00","description":"Hangzhou Jiuyuan Gene Engineering Co., Ltd. (HKG: 2566) announced receiving tacit clinical approval from China's National Medical Products Administration (NMPA) for JY47, a SIRP\u03b1\u2011targeted monoclonal antibody, enabling initiation of clinical trials in metabolic dysfunction\u2011associated steatohepatitis (MASH) with liver fibrosis \u2013 a novel immunometabolic approach to the growing non\u2011alcoholic steatohepatitis therapeutic market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59891#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59891"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59891#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jiuyuan Gene Engineering Secures NMPA Approval for JY47 \u2013 SIRP\u03b1 Antibody Enters MASH Clinical Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59891","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59891"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59891\/revisions"}],"predecessor-version":[{"id":59893,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59891\/revisions\/59893"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59891"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59891"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59891"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}